pyrazines has been researched along with rb 90740 in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 8 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Adams, GE; Cole, S; Haigh, A; Jenner, T; Naylor, MA; Robertson, N; Siemann, D; Stephens, MA; Stratford, IJ | 1 |
| Adams, GE; Fielden, EM; Naylor, MA; Nolan, J; O'Neill, P; Stratford, IJ; Sutton, BM | 1 |
| Adams, GE; Cole, S; Fielden, EM; Naylor, MA; Reeves, NJ; Stratford, IJ; Sutton, BM | 1 |
| Barham, HM; Stratford, IJ | 1 |
| Hall, EJ; Hei, TK; Liu, SX | 1 |
| Dennis, MF; Everett, SA; Naylor, MA; Patel, KB; Priyadarsini, KI; Stratford, IJ; Stratford, MR; Tracy, M; Wardman, P | 1 |
| Barham, HM; Chinje, EC; Inglis, R; Stratford, IJ | 1 |
| Adams, GE; Hall, EJ; Hei, TK; Laderoute, KR; Langmuir, VK; Liu, SX; Mendonca, HL; Naylor, MA; Sutherland, RM | 1 |
8 other study(ies) available for pyrazines and rb 90740
| Article | Year |
|---|---|
Fused pyrazine mono-N-oxides as bioreductive drugs. III. Characterization of RB 90740 in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Cell Survival; Cricetinae; DNA Damage; Female; Male; Mice; Mice, Inbred C3H; Neoplasms, Experimental; Pyrazines; Tumor Cells, Cultured | 1995 |
Radiolytic and photochemical reduction of the hypoxic cytotoxin 1,2-dihydro-8-(4-methylpiperazinyl)-4-phenylimidazo [1,2-a] pyrido [3,2-e] pyrazine 5-oxide (RB90740) and a potential mechanism for hypoxia-selective toxicity.
Topics: Animals; Antineoplastic Agents; Cell Hypoxia; Humans; Hydrogen-Ion Concentration; Mice; Oxidation-Reduction; Photochemistry; Pyrazines; Tumor Cells, Cultured | 1994 |
Pharmacokinetics, metabolism and distribution of 1,2-dihydro-8-(4-methylpiperazinyl)-4-phenylimidazo [1,2-A] pyrido [3,2-E] pyrazine-5-oxide in C3H mice.
Topics: Animals; Antineoplastic Agents; Mice; Mice, Inbred C3H; Neoplasms, Experimental; Pyrazines; Tissue Distribution | 1994 |
Enzymology of the reduction of the novel fused pyrazine mono-n-oxide bioreductive drug, RB90740 roles for P450 reductase and cytochrome b5 reductase.
Topics: Animals; Antineoplastic Agents; Biotransformation; Cytochrome Reductases; Cytochrome-B(5) Reductase; Female; Mice; Mice, Inbred C3H; Microsomes, Liver; NADPH-Ferrihemoprotein Reductase; Oxidation-Reduction; Pyrazines | 1996 |
Oncogenic potential of bifunctional bioreductive drugs.
Topics: Animals; Antineoplastic Agents; Aziridines; Cell Survival; Cell Transformation, Neoplastic; Indolequinones; Indoles; Mice; Mice, Inbred C3H; Mitomycin; Oxidation-Reduction; Pyrazines; Structure-Activity Relationship | 1996 |
Chemical properties which control selectivity and efficacy of aromatic N-oxide bioreductive drugs.
Topics: Antineoplastic Agents; Free Radicals; Hydrogen-Ion Concentration; Oxidation-Reduction; Oxides; Pulse Radiolysis; Pyrazines; Tirapazamine; Triazines | 1996 |
Development and validation of a spectrophotometric assay for measuring the activity of NADH: cytochrome b5 reductase in human tumour cells.
Topics: Animals; Antineoplastic Agents; Biotransformation; Cytochrome Reductases; Cytochrome-B(5) Reductase; Female; Humans; Hydroxymercuribenzoates; Mice; Mice, Inbred C3H; Neoplasm Proteins; Neoplasms; Protease Inhibitors; Pyrazines; Reproducibility of Results; Spectrophotometry; Tumor Cells, Cultured | 1996 |
Fused pyrazine mono-n-oxides as bioreductive drugs. II Cytotoxicity in human cells and oncogenicity in a rodent transformation assay.
Topics: Animals; Antineoplastic Agents; Cell Hypoxia; Cell Transformation, Neoplastic; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; HT29 Cells; Humans; Mice; Mice, Inbred C3H; Pyrazines; Radiobiology; Structure-Activity Relationship; Tumor Cells, Cultured | 1996 |